CO6811807A2 - Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta - Google Patents

Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta

Info

Publication number
CO6811807A2
CO6811807A2 CO13168686A CO13168686A CO6811807A2 CO 6811807 A2 CO6811807 A2 CO 6811807A2 CO 13168686 A CO13168686 A CO 13168686A CO 13168686 A CO13168686 A CO 13168686A CO 6811807 A2 CO6811807 A2 CO 6811807A2
Authority
CO
Colombia
Prior art keywords
ligands
bind
receptor
beta
growth factor
Prior art date
Application number
CO13168686A
Other languages
English (en)
Inventor
Andrew Beaton
Caroline Dimech
Peter Franz Ertl
Susannah Karen Ford
Ruth Mcadam
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45444622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6811807(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO6811807A2 publication Critical patent/CO6811807A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
CO13168686A 2011-01-06 2013-07-16 Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta CO6811807A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161430235P 2011-01-06 2011-01-06

Publications (1)

Publication Number Publication Date
CO6811807A2 true CO6811807A2 (es) 2013-12-16

Family

ID=45444622

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13168686A CO6811807A2 (es) 2011-01-06 2013-07-16 Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta

Country Status (21)

Country Link
US (3) US9150651B2 (es)
EP (1) EP2661449B1 (es)
JP (2) JP6062375B2 (es)
KR (1) KR101886898B1 (es)
CN (1) CN103443126B (es)
AU (1) AU2016203609A1 (es)
BR (1) BR112013016917A2 (es)
CA (1) CA2823104A1 (es)
CL (1) CL2013001975A1 (es)
CO (1) CO6811807A2 (es)
CR (1) CR20130376A (es)
DO (1) DOP2013000162A (es)
EA (1) EA201391012A1 (es)
ES (1) ES2627299T3 (es)
IL (1) IL227254A0 (es)
MA (1) MA34820B1 (es)
MX (1) MX2013007936A (es)
PE (1) PE20140982A1 (es)
SG (1) SG191762A1 (es)
WO (1) WO2012093125A1 (es)
ZA (1) ZA201304726B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
MA34820B1 (fr) * 2011-01-06 2014-01-02 Glaxo Group Ltd Ligandise se liant au récepteur ii du tgf-bêta
EP2723769B2 (en) * 2011-06-23 2022-06-15 Ablynx NV Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2970452A2 (en) * 2013-03-15 2016-01-20 AC Immune S.A. Anti-tau antibodies and methods of use
US20150056199A1 (en) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
EP3071215B1 (en) 2013-11-21 2020-01-08 The Brigham and Women's Hospital, Inc. Compositions and methods for treating pulmonary hypertension
EP3094649A1 (en) * 2014-01-15 2016-11-23 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn-binding properties
EP3693004A1 (en) * 2014-08-01 2020-08-12 The Brigham and Women's Hospital, Inc. An inhibitor of gdf-15 for use in treating fibrosis
NZ737205A (en) 2015-06-24 2024-07-26 F Hoffmann La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
KR20180035884A (ko) 2015-08-04 2018-04-06 악셀레론 파마 인코포레이티드 골수증식성 장애를 치료하기 위한 방법
US20190023809A1 (en) * 2015-09-03 2019-01-24 The Children's Mercy Hospital Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof
MY192668A (en) 2015-10-02 2022-08-30 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
HUE057241T2 (hu) * 2015-11-13 2022-04-28 Ablynx Nv Javított, szérumalbumint kötõ immunoglobulin variábilis domének
WO2017175145A1 (en) 2016-04-05 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Inhibition of tgfbeta in immunotherapy
WO2018204594A1 (en) 2017-05-04 2018-11-08 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof
GB201807693D0 (en) * 2018-05-11 2018-06-27 Autolus Ltd Cell
WO2020009248A1 (ja) * 2018-07-04 2020-01-09 京都府公立大学法人 眼組織の線維化抑制用組成物
CA3165605A1 (en) * 2019-12-24 2021-07-01 Merus N.V. Tgf-beta-rii binding proteins
KR102314157B1 (ko) * 2020-01-10 2021-10-19 주식회사 뉴클릭스바이오 TGF-β 수용체에 특이적으로 결합하는 항체 및 이의 이용방법
WO2022099090A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. Heterodimeric antibodies that bind tgfbrii
WO2022172085A2 (en) 2021-02-15 2022-08-18 Takeda Pharmaceutical Company Limited Cell therapy compositions and methods for modulating tgf-b signaling

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
EP1572936A2 (en) 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP2135879A3 (en) 2002-06-28 2010-06-23 Domantis Limited Ligand
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
EP2357237A1 (en) 2003-05-14 2011-08-17 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
DK1639011T3 (da) 2003-06-30 2009-02-16 Domantis Ltd Pegylerede enkelt-domæne antistoffer (dAb)
AU2004284090A1 (en) 2003-10-24 2005-05-06 Avidia, Inc. LDL receptor class A and EGF domain monomers and multimers
EP1729795B1 (en) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
EP2172553A1 (en) 2004-03-24 2010-04-07 Domantis Limited Gas1 universal leader
GB0418651D0 (en) 2004-08-20 2004-09-22 Medical Res Council Method
US20070012251A1 (en) 2005-07-07 2007-01-18 Martin Zucker Seal arrangement with corrosion barrier and method
WO2007085815A2 (en) 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
JO3096B1 (ar) 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
CA2768981A1 (en) 2009-07-29 2011-02-03 Rudolf Maria De Wildt Ligands that bind tgf-beta receptor rii
WO2011056997A1 (en) * 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
MA34820B1 (fr) * 2011-01-06 2014-01-02 Glaxo Group Ltd Ligandise se liant au récepteur ii du tgf-bêta

Also Published As

Publication number Publication date
AU2012204867A1 (en) 2013-07-25
CA2823104A1 (en) 2012-07-12
US20130302335A1 (en) 2013-11-14
SG191762A1 (en) 2013-08-30
PE20140982A1 (es) 2014-08-22
AU2012204867B2 (en) 2016-03-10
AU2012204867A8 (en) 2016-03-24
CN103443126B (zh) 2016-11-23
AU2016203609A1 (en) 2016-06-16
EP2661449B1 (en) 2017-03-22
WO2012093125A1 (en) 2012-07-12
US20180086835A1 (en) 2018-03-29
JP2017051191A (ja) 2017-03-16
ES2627299T3 (es) 2017-07-27
ZA201304726B (en) 2014-03-26
MX2013007936A (es) 2013-08-09
BR112013016917A2 (pt) 2017-04-04
MA34820B1 (fr) 2014-01-02
NZ612839A (en) 2014-09-26
KR20140036146A (ko) 2014-03-25
CN103443126A (zh) 2013-12-11
DOP2013000162A (es) 2014-01-15
IL227254A0 (en) 2013-09-30
JP6062375B2 (ja) 2017-01-18
KR101886898B1 (ko) 2018-08-08
CR20130376A (es) 2013-11-29
EP2661449A1 (en) 2013-11-13
JP2014504866A (ja) 2014-02-27
JP6453289B2 (ja) 2019-01-16
EA201391012A1 (ru) 2014-01-30
US20150361176A1 (en) 2015-12-17
US9850307B2 (en) 2017-12-26
CL2013001975A1 (es) 2014-03-07
US9150651B2 (en) 2015-10-06

Similar Documents

Publication Publication Date Title
CO6811807A2 (es) Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta
FR23C1023I2 (fr) Anticorps anti-il-36r
DK2934584T3 (da) Anti-gdf15-antistoffer
CO7020875A2 (es) Anticuerpos humanizados que reconocen la alfa-sinucleina
DK2850101T3 (da) Anti-FcRn-antistoffer
CO6811812A2 (es) Anticuerpo anti-b7-h3
DK3156416T3 (da) Sekvenssymmetriske modificerede bispecifikke igg4-antistoffer
DK2607695T3 (da) Planetgearsystem
CR20140127A (es) Anticuerpo anti-abtcr
BR112013019150A2 (pt) engenharia do âmbito da imunoglobulina
HK1213906A1 (zh) 針對β澱粉樣蛋白的抗體
DE112012002386A5 (de) Hochsetzsteller
BR112014025037A2 (pt) anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
DK2828292T3 (da) Jcv-neutraliserende antistoffer
DK2931748T3 (da) Bmp-6-antistoffer
DK3431504T3 (da) Antiphospholipase d4-antistof
DK3521315T3 (da) Anti-transglutaminase-2-antistoffer
CO7111295A2 (es) Anticuerpo anti-rob04
DK2935330T3 (da) Anti-notch3-antistoffer
CO6841994A2 (es) Anticuerpos
HK1206610A1 (en) Fully human antibodies that bind to vegfr2 vegfr2
FI20126010A (fi) Lähdekohteiden muuntaminen kohdekohteiksi
DK3087177T3 (da) Antistofproduktion ex vivo
BRDI7105449S (pt) Configuração aplicada á organizador
TH1301003092B (th) การปรับปรุงซึ่งเกี่ยวข้องกับการประหยัดเชื้อเพลิง